Bristol-Myers Squibb Aktie
58,00USD | 0,25USD | 0,43% |
WKN: 850501 / ISIN: US1101221083
Aktionärsstruktur
Inhaber | in % |
---|---|
Freefloat | 99,92 |
The Vanguard Group, Inc. | 9,77 |
Vanguard Group, Inc. (Subfiler) | 8,83 |
State Street Corp. | 4,58 |
Vanguard Total Stock Market ETF | 3,15 |
Charles Schwab Investment Management, Inc. | 3,01 |
BlackRock Fund Advisors | 2,92 |
Vanguard 500 Index Fund | 2,65 |
Schwab US Dividend Equity ETF | 2,52 |
JPMorgan Investment Management, Inc. | 2,48 |
BlackRock Institutional Trust Co. NA | 2,23 |
Geode Capital Management LLC | 2,13 |
Capital Research & Management Co. (International Investors) | 2,10 |
Norges Bank (13F) | 1,61 |
SPDR S&P 500 ETF Trust | 1,23 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 30 000 | 30 250 | 32 200 | 34 300 | 34 100 |
Umsatz pro Mitarbeiter in Mio. EUR | 0,87 | 1,41 | 1,44 | 1,35 | 1,32 |
Bilanz (in Mio. USD) - Aktiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 29 354 | 30 192 | 33 262 | 27 273 | 31 770 |
Summe Anlagevermögen | 100 590 | 88 289 | 76 052 | 69 547 | 63 389 |
Summe Aktiva | 129 944 | 118 481 | 109 314 | 96 820 | 95 159 |
Bilanz (in Mio. USD) - Passiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Summe Fremdkapital | 78 246 | 80 599 | 73 308 | 65 702 | 65 674 |
Summe Eigenkapital | 51 698 | 37 882 | 36 006 | 31 118 | 29 485 |
Summe Passiva | 129 944 | 118 481 | 109 314 | 96 820 | 95 159 |
Adresse
Route 206 & Province Line Road, 08543 Princeton | |
Telefon | +1 (609) 252-4621 |
Internet | http://www.bms.com |
Management
Abed Al-Nasser Odeh
Manager |
Adam Lenkowsky
Chief Commercialization Officer & Executive VP |
Amanda Poole
Chief Human Resources Officer & Executive VP |
Amy Fallone
Secretary |
Cari Gallman
Executive Vice President-Corporate Affairs |
Catalina Vargas
Chief Of Staff |
Christopher S. Boerner
Chairman & Chief Executive Officer |
Cynthia Piccirillo
Group Director |
David V. Elkins
Chief Financial Officer & Executive Vice President |
Deepak L. Bhatt
Independent Director |
Derica W. Rice
Independent Director |
Estelle Vester-Blokland
Senior VP-Global Medical Affairs |
Frank Incontrera
Director-Global Energy Services |
Greg Meyers
Chief Digital & Technology Officer |
Julia A. Haller
Independent Director |
Karen H. Vousden
Independent Director |
Kimberly McCutcheon Jablonski
Chief Compliance & Ethics Officer |
Krisztina Nemenyi
Head-Asia Pacific Global Regulatory Affairs |
Laura Hortas
Head-Corporate & Employee Communications |
Louis S. Schmukler
President-Global Product Development & Supply |
MARIA V LOPEZ BRESNAHAN
Vice President |
Manuel Hidalgo Medina
Independent Director |
Mark Rolfe
Senior Vice President |
Melissa Seymour
Chief Quality Officer |
Michael R. McMullen
Independent Director |
Monica Shaw
Senior Vice President-Major Markets |
Paula A. Price
Independent Director |
Peter J. Arduini
Independent Director |
Phil Holzer
Senior Vice President & Controller |
Phyllis R. Yale
Independent Director |
Robert M. Plenge
Chief Research Officer, Head-Research & EVP |
Samit Hirawat
Chief Medical Officer & EVP-Drug Development |
Sandra Leung
Executive Vice President & General Counsel |
Teresa M. Foy
Senior VP-Immuno Oncology & Cell Therapy |
Theodore Rapp Samuels
Lead Independent Director |
William Perhacs
Director-Global Energy & Sustainability Services |
Zack Newman
Associate Director-Global Sustainability Strategy |